Novo Nordisk A/S Class B · OMXCOP:NOVO_B
Novo Nordisk A/S Class B — Bear Stearns Healthcare Conference 2007
48 slides from Novo Nordisk A/S Class B's conference presentation, Feb 27, 2007
Slide 1: Bear Stearns Healthcare Conference
Bear Stearns Healthcare Conference Bear Stearns Healthcare Conference Jakob Riis Senior Vice President, International Marketing London, 27 February 2007
Slide 2: Forward-looking statements
Bear Stearns Healthcare Conference 27 February 2007 Slide no 2 Forward-looking statements The above contains forward-looking statements as the term is defined in the US Private Securities Litigation Reform Act of 1995. This in particular relates to information included under the headings ‘Outlook 20
Slide 3: Agenda
Bear Stearns Healthcare Conference 27 February 2007 Slide no 3 Agenda • Highlights and strategy • Sales update • R&D update • Financials
Slide 4: Highlights for 2006
Bear Stearns Healthcare Conference 27 February 2007 Slide no 4 Highlights for 2006 Market development: • Robust sales growth: +15% as reported, +16% in local currencies • Sales growth driven by modern insulins: +48% as reported • NovoSeven® growth continued: +11% as reported • Norditropin® showed st
Slide 5: Highlights for 2006, cont’d
Bear Stearns Healthcare Conference 27 February 2007 Slide no 5 Highlights for 2006, cont’d R&D – diabetes care: • Recruitment completed in global liraglutide phase 3 study • Initiation of phase 3 study of liraglutide in Japan • Initiation of phase 2 dose-ranging study of liraglutide within obesity •
Slide 6: Novo Nordisk’s corporate strategy
Bear Stearns Healthcare Conference 27 February 2007 Slide no 6 Novo Nordisk’s corporate strategy Focus areas Compounds/Capabilities Strategic focus Insulin Drug delivery and protein expertise 1. Diabetes Maintain Leadership GLP-1 Global specialist reach Other proteins rFVIIa 2. Biopharmaceuticals rF
Slide 7: Insulin world market leader with 52% market share
Bear Stearns Healthcare Conference 27 February 2007 Slide no 7 Insulin world market leader with 52% market share Europe North America Novo Nordisk #1 Novo Nordisk #1 Market share 57% Japan & Oceania Market share: 41% Novo Nordisk #1 Market share: 76% International Operations Novo Nordisk #1 Market s
Slide 8: Growth in Novo Nordisk’s insulin franchise looks set to continue
Bear Stearns Healthcare Conference 27 February 2007 Slide no 8 Growth in Novo Nordisk’s insulin franchise looks set to continue IMS developed world insulin Rapid increase in number of market growth people with diabetes Volume: 5.4% 200 2007 2025 180 Value: 160 2007: 246 million 10.9% 140 2025: 380 m
Slide 9: Sales update
Bear Stearns Healthcare Conference 27 February 2007 Slide no 9 Sales update
Slide 10: Key products continue to drive growth – full year 06
Bear Stearns Healthcare Conference 27 February 2007 Slide no 10 Key products continue to drive growth – full year 2006 Sales as reported Growth analysis Other Norditropin® +2% Local currencies Growth Share of +19% growth 5% 9% Diabetes care Modern insulins 50% 69% +16% Human insulin and 1% 3% NovoSe
Slide 11: Modern insulins
Bear Stearns Healthcare Conference 27 February 2007 Slide no 11 Modern insulins Modern insulin sales development Modern insulin sales as reported Levemir® +40% DKK 1.4bn 3,200 +187% NovoRapid® DKK 5.6bn 2,800 13% NovoMix® +36% 2,400 DKK 3.8bn DKK million +42% 2,000 35% 52% 1,600 1,200 800 400 0 Q1 Q
Slide 12: A continued increase in modern insulin market share
Bear Stearns Healthcare Conference 27 February 2007 Slide no 12 A continued increase in modern insulin market share IMS world modern insulin Modern insulin penetration market shares, volume 80% 70% Novo Nordisk 60% Eli Lilly 49% Modern insulin 50% Sanofi-Aventis 7% 40% 30% Human insulin 20% 10% 0% Q
Slide 13: Levemir reinforces European modern insulin market leadership
Bear Stearns Healthcare Conference 27 February 2007 Slide no 13 Levemir® reinforces European modern insulin market leadership Share of total modern insulin Novo Nordisk’s share of long- sales in Europe acting modern insulin in Europe 21% 22% 60% Novo Nordisk Eli Lilly 20% Sanofi-Aventis 18% 50% 16%
Slide 14: NovoSeven sales development
DKK million 0 200 400 600 800 1,000 1,200 1,400 1,600 Q1 2002 NovoSeven® NovoSeven® sales development Q4 2006 +6% Key observations • Growth in the fourth quarter of 6% as reported, 11% in local Bear Stearns Healthcare Conference currencies • Sales growth in all regions • North American sales picked
Slide 15: Norditropin sales development
Bear Stearns Healthcare Conference 27 February 2007 Slide no 15 Norditropin® Norditropin® Global growth hormone sales development market shares, value 60% Pfizer Novo Nordisk +15% Genentech 900 50% Eli Lilly 800 Serono 700 40% DKK million 600 28% 500 30% 23% 400 20% 300 200 10% 100 0 0% Q1 Q4 Q1 Q3
Slide 16: Sales by region – full year 2006
Bear Stearns Healthcare Conference 27 February 2007 Slide no 16 Sales by region - full year 2006 Sales as reported Growth analysis Japan & Oceania -1% Europe Local Growth Share of +9% currencies growth 12% International Europe 9% 23% Operations North America 29% 53% +17% 18% 38% International 17% 20
Slide 17: US diabetes performance
Bear Stearns Healthcare Conference 27 February 2007 Slide no 17 US insulin market share US diabetes performance development Novo Nordisk’s US insulin sales development Index 80% local currencies 70% Novo Nordisk 500 Eli Lilly 450 60% Sanofi-Aventis 400 % : 43 50% 350 AGR C 300 40% 250 200 30% 150 20
Slide 18: Levemir launch in the US
Bear Stearns Healthcare Conference 27 February 2007 Slide no 18 Levemir® launch in the US • High level of formulary coverage: • Increase in US sales force by 700 Levemir® share of total basal close to 75% of total lives at Key observations modern insulin prescriptions to 1,900 to drive further 6% pe
Slide 19: R&D update
Bear Stearns Healthcare Conference 27 February 2007 Slide no 19 R&D update
Slide 20: Development portfolio – diabetes
Bear Stearns Healthcare Conference 27 February 2007 Slide no 20 Development portfolio – diabetes Compound Type Indication Phase Levemir® Modern insulin Types 1+2 Launched in US, Europe, etc. Filed in JP NovoMix® 50 and 70 Modern insulin Types 1+2 Approved in Europe Filed in US Liraglutide GLP-1 anal
Slide 21: Development portfolio – haemostasis
Bear Stearns Healthcare Conference 27 February 2007 Slide no 21 Development portfolio – haemostasis Compound Indication Phase NovoSeven® Heat-stable formulation Preparing for filing NovoSeven® Intracerebral haemorrhage Phase 3 NovoSeven® Trauma Phase 3 NovoSeven® Prophylaxis Phase 2 completed NovoSe
Slide 22: Development portfolio - other biopharmaceuticals
Bear Stearns Healthcare Conference 27 February 2007 Slide no 22 Development portfolio - other biopharmaceuticals Compound Indication Phase Activelle® low dose Hormone replacement therapy Approved in US; Filed in Europe Vagifem® low dose Hormone replacement therapy Phase 3 Norditropin® APCD1 Phase 2
Slide 23: Financials
Bear Stearns Healthcare Conference 27 February 2007 Slide no 23 Financials
Slide 24: Financial results
Bear Stearns Healthcare Conference 27 February 2007 Slide no 24 Financial results DKK million 2006 2005 % change Sales 38,743 33,760 15 Gross profit 29,158 24,583 19 Gross margin 75.3% 72.8% Sales and distribution costs 11,608 9,691 20 Percent of sales 30.0% 28.7% Research and development costs 6,31
Slide 25: Strong gross margin development
Bear Stearns Healthcare Conference 27 February 2007 Slide no 25 Strong gross margin development Gross margin improvement analysis Key observations 76% • Underlying improvement of 210 bp basis points 1 0 75% +2 75.3 • Productivity gains prime 74% bp contributor – reflecting significant 0 73.2 +9 0.4
Slide 26: Long-term financial targets
Bear Stearns Healthcare Conference 27 February 2007 Slide no 26 Long-term financial targets Long-term financial targets In % Financial 2002 2003 2004 2005 2006 targets Operating profit growth 9.6 8.4 8.7 15.9 12.7 15 Operating margin 23.8 24.6 24.0 24.0 23.5 25 Cash to earnings* 12.1 79.6 85.3 82.4
Slide 27: Outlook 2007
Bear Stearns Healthcare Conference 27 February 2007 Slide no 27 Outlook 2007 • Sales growth expectations: • More than 10% measured in local currencies Key currency rates • Sales growth in DKK lower than sales growth in DKK 2006 2007 Current local currencies per 100 averag average rate* e • Operating
Slide 28: Novo Nordisk - concluding remarks
Bear Stearns Healthcare Conference 27 February 2007 Slide no 28 Novo Nordisk - concluding remarks • #1 in the global injection device • #1 in the global modern insulin • #1 in the global insulin market Key growth drivers • #1 in the global haemophilia • Leadership in diabetes care with Strategic pos
Slide 29: Investor information
Bear Stearns Healthcare Conference 27 February 2007 Slide no 29 Investor information Share information Investor Relations Novo Nordisk’s B shares are contacts listed on the stock exchanges in Novo Nordisk A/S Investor Relations Copenhagen and London. Its Novo Allé, DK2880 Bagsværd Fax (+45) 4443 66
Slide 30: Appendices
Bear Stearns Healthcare Conference 27 February 2007 Slide no 30 Appendices
Slide 31: Currency development: USD and JPY
Bear Stearns Healthcare Conference 27 February 2007 Slide no 31 Currency development: USD and JPY Spot rates Quarterly average Annual average 660 628 640 621 USD/DKK 620 612 600 577 573 580 592 594 586 560 568 540 Q105 Q205 Q305 Q405 Q106 Q206 Q306 Q406 6.0 Spot rates Quarterly average Annual averag
Slide 32: Solid insulin market growth - Novo Nordisk market leadership
Bear Stearns Healthcare Conference 27 February 2007 Slide no 32 Solid insulin market growth - Novo Nordisk market leadership Market size Growth rates Novo Nordisk market share Market Novo Nordisk US 11.2% 41% 39% 3.9% Europe 4.1% 51% 57% 5.6% Japan 7.1% 74% 5% 7.2% World 6.6% 52% 100% 5.0% Note: Vol
Slide 33: Insulin growth driven by NovoRapid and NovoMix
Bear Stearns Healthcare Conference 27 February 2007 Slide no 33 Insulin growth driven by NovoRapid® and NovoMix® NovoRapid® share of short- NovoMix® share of acting modern insulin premixed modern insulin 70% 70% 66% 60% 60% 53% 50% 50% 40% 40% 30% 30% 20% 20% 10% 10% 0% 0% Q1 Q3 Q1 Q3 2002 2006 2002
Slide 34: European modern insulin conversion - NovoRapid
Bear Stearns Healthcare Conference 27 February 2007 Slide no 34 European modern insulin conversion - NovoRapid® Modern insulin penetration short-acting modern insulin Share of short-acting segment NovoRapid® 30% 25% Human insulin 20% Humalog 55% 15% 10% Modern insulin 5% Apidra 0% Q1 Q3 Q1 Q3 2000 2
Slide 35: European modern insulin conversion - NovoMix
Bear Stearns Healthcare Conference 27 February 2007 Slide no 35 European modern insulin conversion - NovoMix® 30 Modern insulin penetration premixed segment Share of premixed segment 25% 20% NovoMix® 30 Human insulin 15% 10% Humalog Mix 25 5% 35% Modern insulin 0% Q1 Q3 Q1 Q3 2000 2006 2000 2006 Not
Slide 36: European modern insulin conversion - Levemir
Bear Stearns Healthcare Conference 27 February 2007 Slide no 36 European modern insulin conversion - Levemir® Modern insulin penetration Novo Nordisk’s share of long- long-acting segment acting modern insulin in Europe 22% 21% 20% 18% 16% Human insulin 14% 12% 10% 8% 47% 6% 4% 2% Modern insulin 0% Q
Slide 37: US modern insulin conversion - NovoLog
Bear Stearns Healthcare Conference 27 February 2007 Slide no 37 US modern insulin conversion - NovoLog® Modern insulin penetration short-acting segment Share of short-acting segment 50% Human insulin 40% Humalog 67% 30% NovoLog® 20% 33% Modern insulin 10% 0% Q1 Q3 Q1 Q3 2000 2006 2000 2006 Note: Qua
Slide 38: US modern insulin conversion - NovoLog Mix 70/30
Bear Stearns Healthcare Conference 27 February 2007 Slide no 38 US modern insulin conversion - NovoLog® Mix 70/30 Modern insulin penetration premixed segment Share of premixed segment 30% 25% Humalog Mix 25 Human insulin 20% 15% NovoLog® Mix 70/30 10% 31% 5% Modern insulin 0% Q1 Q3 Q1 Q3 2000 2006 2
Slide 39: US modern insulin conversion - Levemir
Bear Stearns Healthcare Conference 27 February 2007 Slide no 39 US modern insulin conversion - Levemir® Modern insulin penetration Levemir® share of total long-acting long-acting segment modern insulin prescriptions 6% 5% Human insulin 4% 3% 60% 2% 1% Modern insulin 0% Q1 Q3 April December 2000 2006
Slide 40: Insulin segmentation - Europe and the US
Bear Stearns Healthcare Conference 27 February 2007 Slide no 40 Insulin segmentation - Europe and the US Europe US 60% 60% 50% 50% 40% 40% 30% 30% 20% Long-acting 20% Long-acting Premix Premix 10% 10% Short-acting Short-acting 0% 0% Q1 Q3 Q1 Q3 2000 2006 2000 2006 Note: Quarterly data, volume figure
Slide 41: Switch from Lantus to Levemir improved HbA1c, while reducing hypoglycaemia and weight
Bear Stearns Healthcare Conference 27 February 2007 Slide no 41 Switch from Lantus to Levemir® improved HbA1c, while reducing hypoglycaemia and weight 10 No. hypoglycaemic episodes /patient year 7.8 HbA1c change: -0.59 %-points vs. Lantus Change in body weight: -0.8 kilograms 2.2 * 0.5 * * 0.1 0.3 0
Slide 42: Human versus all-analogue basal-bolus in type 1 diabetes
Bear Stearns Healthcare Conference 27 February 2007 Slide no 42 Human versus all-analogue basal-bolus in type 1 diabetes: Switch to Levemir® + NovoRapid® 60 55 No. hypoglycaemic episodes/patient year 50 HbA1c change (%-points): -0.65 vs. human basal-bolus 40 30 20 18.3 * 11 10 * * 1.7 1.2 0.0 0 Over
Slide 43: Biosimilars compete in a declining segment
Bear Stearns Healthcare Conference 27 February 2007 Slide no 43 Biosimilars compete in a declining segment Modern insulin conversion in IMS world markets Modern insulin 49% Patent protected Human insulin 2000 Q3 2006 2011 Notes: Quarterly data based on volume figures. From Q3 2006 onwards it is esti
Slide 44: Insulin is the ultimate treatment
Bear Stearns Healthcare Conference 27 February 2007 Slide no 44 Insulin is the ultimate treatment Insulin is the ultimate treatment Key observations • A clear focus on the need for intensifying treatment of diabetes, both via the use of OADs and insulin -Cell function • The number of type 2 patient
Slide 45: Insulin secretion
Bear Stearns Healthcare Conference 27 February 2007 Slide no 45 Insulin secretion 800 People without diabetes Insulin Secretion (pmol/min) 700 Type 2 diabetes 600 500 400 300 200 100 0600 1000 1400 1800 2200 0200 0600 Source: O'MEARA et al. Am. J. Medicine, 1990; 89.
Slide 46: Attractive profile of rFVIIa analogue
Bear Stearns Healthcare Conference 27 February 2007 Slide no 46 Attractive profile of rFVIIa analogue Velocity (mm*100/sec) 20 Severe haemophilia A + rFVIIa 2 µg/mL + NN1731 2 µg/mL • NN1731 has been found to 15 Healthy male induce a faster rate of thrombin formation than 10 obtainable with NovoSeve
Slide 47: Faster haemostasis leads to - a unique mechanism of action
FVIIa/NovoSeven® NovoSeven® A bleeding episode Tissue factor Faster haemostasis leads to • Fewer transfusions / transfusion- free surgery Bear Stearns Healthcare Conference • Reduced re-bleeding • Faster recovery • Reduced morbidity and mortality 27 February 2007 • Improved quality of life Slide no
Slide 48: Anti-KIR being developed in collaboration with Innate Pharma
Bear Stearns Healthcare Conference 27 February 2007 Slide no 48 Anti-KIR being developed in collaboration with Innate Pharma Mode of action Key observations Anti-KIR MoA • Unmet need in AML Tumour • Most common leukaemia in NK Cell adults: around 12,000 new cases per year in the US of which 75% die
Novo Nordisk — Bear Stearns Healthcare Conference 2007 on 6ix